Printer Friendly

Combination Therapy Using Chugai Pharmaceutical's Chronic Hepatitis-C Agents PEGASYS and Rivabirin Granted Priority Review Status by Government.

Tokyo, Japan, Sept 14, 2005 - (JCNN) - Chugai Pharmaceutical announced on September 13 that the Ministry of Health, Labor and Welfare (MHLW) has granted the company with a priority review status for a combination therapy of PEGASYS (pegylated interferon alpha-2a) and rivabirin (planned trade name COPEGUS), two agents manufactured by Chugai.

PEGASYS is a pegylated interferon agent that treats chronic hepatitis C infection with a once-a-week dosage. The monotherapy using PEGASYS has been covered by the National Health Insurance since December 2003.

With this move, Chugai expects to obtain approval at the earliest date as possible and contribute to the treatment of chronic hepatitis C.

Results of phase III clinical trials for the combination therapy of PEGASYS and rivabirin were presented at the 41st Annual Conference of the Japan Society of Hepatology held in Osaka in June.

Source: JCN http://www.japancorp.net

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Sep 16, 2005
Words:152
Previous Article:Olympus Imaging to Introduce New Entry-level 5-megapixel, 6-megapixel Digital Cameras.
Next Article:Omron Healthcare, Tohoku University Jointly Surveyed 10,000 People on Blood Pressure Measurement.


Related Articles
VERTEX/MITSUBISHI TO DEVELOP HCV ORAL PROTEASE INHIBITOR.
PHARMASSET TO DEVELOP CLEVUDINE FOR HEPATITIS B.
VALEANT BEGINS CLINICAL DEVELOPMENT OF VIRAMIDINE IN JAPAN.
Bristol's BARACLUDE Tablet for Chronic Hepatitis B Virus Infection Granted Priority Review by Government.
MIGENIX INITIATES ENROLLMENT IN PHASE IIB HEPATITIS TRIAL.
Chugai Pharmaceutical to Establish an Oncology Unit.
TELBIVUDINE APPROVED IN SWITZERLAND FOR CHRONIC HEPATITIS B.
Anti-Cancer Agent Avastin(R) Approved in Japan.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |